Dataset Information

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.

ABSTRACT: The contribution of germline copy number variants (CNVs) to risk of developing cancer in individuals with pathogenic BRCA1 or BRCA2 variants remains relatively unknown. We conducted the largest genome-wide analysis of CNVs in 15,342 BRCA1 and 10,740 BRCA2 pathogenic variant carriers. We used these results to prioritise a candidate breast cancer risk-modifier gene for laboratory analysis and biological validation. Notably, the HR for deletions in BRCA1 suggested an elevated breast cancer risk estimate (hazard ratio (HR) = 1.21), 95% confidence interval (95% CI = 1.09-1.35) compared with non-CNV pathogenic variants. In contrast, deletions overlapping SULT1A1 suggested a decreased breast cancer risk (HR = 0.73, 95% CI 0.59-0.91) in BRCA1 pathogenic variant carriers. Functional analyses of SULT1A1 showed that reduced mRNA expression in pathogenic BRCA1 variant cells was associated with reduced cellular proliferation and reduced DNA damage after treatment with DNA damaging agents. These data provide evidence that deleterious variants in BRCA1 plus SULT1A1 deletions contribute to variable breast cancer risk in BRCA1 carriers.

SUBMITTER: Hakkaart C

PROVIDER: S-EPMC9537519 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.

Hakkaart Christopher C Pearson John F JF Marquart Louise L Dennis Joe J Wiggins George A R GAR Barnes Daniel R DR Robinson Bridget A BA Mace Peter D PD Aittomäki Kristiina K Andrulis Irene L IL Arun Banu K BK Azzollini Jacopo J Balmaña Judith J Barkardottir Rosa B RB Belhadj Sami S Berger Lieke L Blok Marinus J MJ Boonen Susanne E SE Borde Julika J Bradbury Angela R AR Brunet Joan J Buys Saundra S SS Caligo Maria A MA Campbell Ian I Chung Wendy K WK Claes Kathleen B M KBM Collonge-Rame Marie-Agnès MA Cook Jackie J Cosgrove Casey C Couch Fergus J FJ Daly Mary B MB Dandiker Sita S Davidson Rosemarie R de la Hoya Miguel M de Putter Robin R Delnatte Capucine C Dhawan Mallika M Diez Orland O Ding Yuan Chun YC Domchek Susan M SM Donaldson Alan A Eason Jacqueline J Easton Douglas F DF Ehrencrona Hans H Engel Christoph C Evans D Gareth DG Faust Ulrike U Feliubadaló Lidia L Fostira Florentia F Friedman Eitan E Frone Megan M Frost Debra D Garber Judy J Gayther Simon A SA Gehrig Andrea A Gesta Paul P Godwin Andrew K AK Goldgar David E DE Greene Mark H MH Hahnen Eric E Hake Christopher R CR Hamann Ute U Hansen Thomas V O TVO Hauke Jan J Hentschel Julia J Herold Natalie N Honisch Ellen E Hulick Peter J PJ Imyanitov Evgeny N EN Isaacs Claudine C Izatt Louise L Izquierdo Angel A Jakubowska Anna A James Paul A PA Janavicius Ramunas R John Esther M EM Joseph Vijai V Karlan Beth Y BY Kemp Zoe Z Kirk Judy J Konstantopoulou Irene I Koudijs Marco M Kwong Ava A Laitman Yael Y Lalloo Fiona F Lasset Christine C Lautrup Charlotte C Lazaro Conxi C Legrand Clémentine C Leslie Goska G Lesueur Fabienne F Mai Phuong L PL Manoukian Siranoush S Mari Véronique V Martens John W M JWM McGuffog Lesley L Mebirouk Noura N Meindl Alfons A Miller Austin A Montagna Marco M Moserle Lidia L Mouret-Fourme Emmanuelle E Musgrave Hannah H Nambot Sophie S Nathanson Katherine L KL Neuhausen Susan L SL Nevanlinna Heli H Yie Joanne Ngeow Yuen JNY Nguyen-Dumont Tu T Nikitina-Zake Liene L Offit Kenneth K Olah Edith E Olopade Olufunmilayo I OI Osorio Ana A Ott Claus-Eric CE Park Sue K SK Parsons Michael T MT Pedersen Inge Sokilde IS Peixoto Ana A Perez-Segura Pedro P Peterlongo Paolo P Pocza Timea T Radice Paolo P Ramser Juliane J Rantala Johanna J Rodriguez Gustavo C GC Rønlund Karina K Rosenberg Efraim H EH Rossing Maria M Schmutzler Rita K RK Shah Payal D PD Sharif Saba S Sharma Priyanka P Side Lucy E LE Simard Jacques J Singer Christian F CF Snape Katie K Steinemann Doris D Stoppa-Lyonnet Dominique D Sutter Christian C Tan Yen Yen YY Teixeira Manuel R MR Teo Soo Hwang SH Thomassen Mads M Thull Darcy L DL Tischkowitz Marc M Toland Amanda E AE Trainer Alison H AH Tripathi Vishakha V Tung Nadine N van Engelen Klaartje K van Rensburg Elizabeth J EJ Vega Ana A Viel Alessandra A Walker Lisa L Weitzel Jeffrey N JN Wevers Marike R MR Chenevix-Trench Georgia G Spurdle Amanda B AB Antoniou Antonis C AC Walker Logan C LC

Communications biology 20221006 1

The contribution of germline copy number variants (CNVs) to risk of developing cancer in individuals with pathogenic BRCA1 or BRCA2 variants remains relatively unknown. We conducted the largest genome-wide analysis of CNVs in 15,342 BRCA1 and 10,740 BRCA2 pathogenic variant carriers. We used these results to prioritise a candidate breast cancer risk-modifier gene for laboratory analysis and biological validation. Notably, the HR for deletions in BRCA1 suggested an elevated breast cancer risk est ...[more]

PMID: 36203093

Similar Datasets

Project description:PurposeSecond primary cancer (SPC) risks after breast cancer (BC) in BRCA1/BRCA2 pathogenic variant (PV) carriers are uncertain. We estimated relative and absolute risks using a novel linkage of genetic testing data to population-scale National Disease Registration Service and Hospital Episode Statistics electronic health records.MethodsWe followed 25,811 females and 480 males diagnosed with BC and tested for germline BRCA1/BRCA2 PVs in NHS Clinical Genetics centers in England between 1995 and 2019 until SPC diagnosis, death, migration, contralateral breast/ovarian surgery plus 1 year, or the 31st of December 2020. We estimated standardized incidence ratios (SIRs) using English population incidences, hazard ratios (HRs) comparing carriers to noncarriers using Cox regression, and Kaplan-Meier 10-year cumulative risks.ResultsThere were 1,840 BRCA1 and 1,750 BRCA2 female PV carriers. Compared with population incidences, BRCA1 carriers had elevated contralateral BC (CBC; SIR, 15.6 [95% CI, 11.8 to 20.2]), ovarian (SIR, 44.0 [95% CI, 31.4 to 59.9]), combined nonbreast/ovarian (SIR, 2.18 [95% CI, 1.59 to 2.92]), colorectal (SIR, 4.80 [95% CI, 2.62 to 8.05]), and endometrial (SIR, 2.92 [95% CI, 1.07 to 6.35]) SPC risks. BRCA2 carriers had elevated CBC (SIR, 7.70 [95% CI, 5.45 to 10.6]), ovarian (SIR, 16.8 [95% CI, 10.3 to 26.0]), pancreatic (SIR, 5.42 [95% CI, 2.09 to 12.5]), and combined nonbreast/ovarian (SIR, 1.68 [95% CI, 1.24 to 2.23]) SPC risks. Compared with females without BRCA1/BRCA2 PVs on testing, BRCA1 carriers had elevated CBC (HR, 3.60 [95% CI, 2.65 to 4.90]), ovarian (HR, 33.0 [95% CI, 19.1 to 57.1]), combined nonbreast/ovarian (HR, 1.45 [95% CI, 1.05 to 2.01]), and colorectal (HR, 2.93 [95% CI, 1.53 to 5.62]) SPC risks. BRCA2 carriers had elevated CBC (HR, 2.40 [95% CI, 1.70 to 3.40]), ovarian (HR, 12.0 [95% CI, 6.70 to 21.5]), and pancreatic (HR, 3.56 [95% CI, 1.34 to 9.48]) SPC risks. Ten-year cumulative CBC, ovarian, and combined nonbreast/ovarian cancer risks were 16%/6.3%/7.8% (BRCA1 carriers), 12%/3.0%/6.2% (BRCA2 carriers), and 3.6%/0.4%/4.9% (noncarriers). Male BRCA2 carriers had higher CBC (HR, 13.1 [95% CI, 1.19 to 146]) and prostate (HR, 5.61 [95% CI, 1.96 to 16.0]) SPC risks than noncarriers.ConclusionSurvivors of BC carrying BRCA1 and BRCA2 PVs are at high SPC risk. They may benefit from enhanced surveillance and risk-reduction measures.

Dataset Information

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.

Publications

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets